null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal debt; OmniAb is essentially debt-free with cash runway funded by licensing milestones and equity; 20% rate rise has negligible P&L impact

Low sensitivity; no significant floating-rate debt; higher rates pressure venture biotech partners' financing, indirectly slowing partnership deal flow

Medium intensity; US-China trade tariffs on metals and components disrupt supply chains.

Transgenic animal colony maintenance (Ligand spin-off legacy facilities) and specialized oligonucleotide/reagent suppliers concentrated in US and China

Minimal direct international revenue; royalty/milestone income denominated in USD contractually, limiting sovereign currency devaluation exposure materially

Primarily US-based operations; partners operate globally but OmniAb revenues are USD-denominated, so direct FX devaluation exposure is very low

Medium intensity; commodities: Steel, Aluminum, Copper, Crude Oil (fuel), Rare Earth Elements, Plastics/Resins; geopolitical: US-China trade tariffs on metals and components disrupt supply chains.

Proprietary transgenic animal platforms (OmniRat, OmniChicken) are internally managed; no single external vendor exceeds 30% of operational input cost

Asset-light biotech platform licensor; cloud disruption would affect data/informatics tools but not core antibody discovery IP or animal facilities

Milestone and royalty model; cloud termination would disrupt bioinformatics workflows but core wet-lab discovery operations remain largely unaffected

High API/platform coupling for partners using OmniAb's discovery ecosystem; switching requires revalidating animal models and datasets, creating 12–24 month lock-in

Low Howey risk; revenue model is B2B licensing of biological IP, not an investment contract; no token, pooled investment, or profit-sharing scheme

Medium

Moderate GDPR/CCPA exposure limited to employee and partner data; no patient data processed directly; compliance cost is manageable and not material

Low antitrust risk; niche transgenic antibody discovery platform with multiple competitors (Humanigen, Ablexis); market share does not approach dominance thresholds

Medium burden; regimes: FAA, DOT, OSHA, EPA, ITAR, FTC; Export controls and defense procurement rules create contract concentration risk.

Predominantly milestone/royalty-based (~80% transactional/variable); annual platform access fees provide modest recurring base (~20% of revenue)

B2B licensing fees, upfront access fees, development milestones, and downstream royalties on partnered drug sales upon commercialization

Tiered licensing: upfront platform access + per-program milestones + royalty rates (low single-digit %); stress scenario shows royalty dependency creates long-dated revenue risk

Moderate; proprietary transgenic platforms confer differentiation, but competition from Ablexis and internal pharma programs caps aggressive price increases

Estimated 70–80% gross margin on licensing/milestone revenue; animal facility operating costs constrain margins below pure software-IP peers

Low free-rider risk; platform access requires contractual licensing; proprietary animal strains cannot be replicated without significant capital and regulatory investment

Sublinear; additional licensing programs require incremental animal colony and scientist capacity but not proportional headcount; platform scales favorably

Low marginal cost per new licensing partner; incremental revenue from milestones/royalties carries 80%+ incremental margin once fixed platform costs are covered

null

At 10x scale, CAC remains low (BD-driven, conference/relationship model); LTV scales with partner drug approvals; unit economics improve significantly with royalty maturation

Weak direct network effects; value derives from proprietary biology and validated datasets, not user-network density; partner success stories create reputational flywheel

-22.0% Return on Assets (Negative equity)

Moderate resilience; large pharma R&D budgets are relatively recession-resistant, but biotech partner funding dries up in downturns, reducing new deal signings

Large pharmaceutical and biopharmaceutical companies seeking novel antibody discovery capabilities for therapeutic programs

Emerging biotech and venture-backed startups accessing OmniAb platforms under cost-efficient licensing to advance preclinical antibody pipelines

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "33-0000 Protective Service Occupations", "37-0000 Building and Grounds Cleaning and Maintenance Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "51-0000 Production Occupations", "53-0000 Transportation and Material Moving Occupations"]

0.3 (HIL — ~30% of characteristic roles agent-automatable)

3.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001846253

OABI